CREDIT SUISSE NEW ISSUE: 6 American Call Warrants on Vifor Pharma Freitag, 26. November 2021 - 09:00
Dear Investor
Please find hereafter the details for these new issues:
Ticker | Valor | ISIN | Underlying | Spot | Strike | Ratio | Maturity | Type | Issue price | Impl. Vola | PDF File |
GVIFCS | 11 505 7199 | CH 115 057 199 5 | Vifor Pharma AG | CHF 109.00 | CHF 100.00 | 50:1 | 16.09.2022 | Call | CHF 0.30 | 28.62% | |
HVIFCS | 11 505 7200 | CH 115 057 200 1 | Vifor Pharma AG | CHF 109.00 | CHF 120.00 | 50:1 | 16.09.2022 | Call | CHF 0.11 | 26.16% | |
IVIFCS | 11 505 7201 | CH 115 057 201 9 | Vifor Pharma AG | CHF 109.00 | CHF 130.00 | 50:1 | 16.09.2022 | Call | CHF 0.07 | 25.68% | |
JVIFCS | 11 505 7202 | CH 115 057 202 7 | Vifor Pharma AG | CHF 109.00 | CHF 100.00 | 50:1 | 16.06.2023 | Call | CHF 0.37 | 28.60% | |
KVIFCS | 11 505 7203 | CH 115 057 203 5 | Vifor Pharma AG | CHF 109.00 | CHF 120.00 | 50:1 | 16.06.2023 | Call | CHF 0.19 | 26.90% | |
LVIFCS | 11 505 7204 | CH 115 057 204 3 | Vifor Pharma AG | CHF 109.00 | CHF 140.00 | 50:1 | 16.06.2023 | Call | CHF 0.09 | 26.12% |
Please visit our website http://www.credit-suisse.com/derivatives to see the complete list of our products.
The warrants will be placed directly in the secondary market. Please call 044/335 76 00.
Kind regards
CREDIT SUISSE AG
Investment Banking
Equity Derivatives & Structured Products
Uetlibergstrasse 231
8070 Zürich, Switzerland
Tel: +41 44 - 335 76 00
Fax: +41 44 - 333 78 08
www.credit-suisse.com
This message may contain confidential, proprietary or legally privileged information and is intended only for the use of the addressee named above. No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this message you are hereby notified that you must not use, disseminate, copy it in any form or take any action in reliance on it. If you have received this message in error please delete it and any copies of it and notify the sender immediately. Credit Suisse Group and its subsidiaries reserve the right to intercept and monitor any e-mail communication through its networks if legally allowed.